Sun Pharma has clarified that reports of a potential $10 billion acquisition of US-based Organon are "speculative." While the company denies current material events, it has a history of high-value acquisitions. Moreover, Indian pharma has had a string of high-value M&As in the past, including Biocon’s $3.3 billion Viatris acquisition in 2022 and Lupin's $880 million bid for Gavis in 2016.
